This should be taken into consideration if, in the future, the ratio has predictive value, as has been demonstrated in the neoadjuvant setting of breast carcinoma patients.35 Interestingly, the HERA trial has failed to confirm that the degree of HER2 amplification influences the benefit from adjuvant trastuzumab. This evidence concerns the gene ERAL1 and breast carcinoma.